2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57/Bl mice

Psychopharmacology

Volumn 183, Issue 3, 2005, Pages 275-284

  Kozela, Ewa ^a   Wrobel, Malgorzata ^a   Kos, Tomasz ^a   Wojcikowski, Jacek ^a   Daniel, Wladyslawa A ^a   Wozniak, Krystyna M ^b   Slusher, Barbara S ^b   Popik, Piotr ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

Dependence; GCP II; mGluR3; NMDA; Opioid; Tolerance

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; METHYL GROUP; MORPHINE; OPIATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DEPENDENCE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERANCE; DRUG WITHDRAWAL; JUMPING; MALE; MASTICATION; MOUSE; MOUSE STRAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PTOSIS; WITHDRAWAL SYNDROME;

AMINO ACIDS; ANIMALS; DRUG TOLERANCE; ENZYME INHIBITORS; GLUTAMATE CARBOXYPEPTIDASE II; MALE; MICE; MICE, INBRED C57BL; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; ORGANOPHOSPHORUS COMPOUNDS; RECEPTORS, METABOTROPIC GLUTAMATE; XANTHENES;

EID: 27844513417     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0182-5     Document Type: Article

References (45)

1. Akaoka H, Aston-Jones G (1991) Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. J Neurosci 11:3830-3839
2. Akaoka H, Aston-Jones G (1993) Indirect serotonergic agonists attenuate neuronal opiate withdrawal. Neuroscience 54:561-565
3. Blasig J, Herz A, Reinhold K, Zieglgansberger S (1973) Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia 33:19-38
4. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) mu-Opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720-723
5. Burlina AP, Skaper SD, Mazza MR, Ferrari V, Leon A, Burlina AB (1994) N-acetylaspartylglutamate selectively inhibits neuronal responses to N-methyl-D-aspartic acid in vitro. J Neurochem 63:1174-1177
6. Calvino B, Lagowska J, Ben-Ari Y (1979) Morphine withdrawal syndrome: differential participation of structures located within the amygdaloid complex and striatum of the rat. Brain Res 177:19-34
7. Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161-170
8. Dewey WL, Harris LS (1975) The tail flick test. In: Ehrenpreis S, Neidle A (eds) Methods in narcotic research. Marcel Dekker, New York, pp 101-109
9. Dzoljic ED, Kaplan CD, Dzoljic MR (1988) Effect of ibogaine on naloxone precipitated withdrawal syndrome in chronic morphine dependent rats. Arch Int Pharmacodyn Ther 294:64-70
10. Fundytus ME, Coderre TJ (1994) Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence. Br J Pharmacol 113:1215-1220
11. Fundytus ME, Coderre TJ (1997) Attenuation of precipitated morphine withdrawal symptoms by acute i.c.v. administration of a group II mGluR agonist. Br J Pharmacol 121:511-514
12. Glare PA (1991) A simple, rapid method for the simultaneous determination of morphine and its principal metabolites in plasma using high-performance liquid chromatography and fluorometric detection. Ther Drug Monit 13:226-232
13. Hamdy MM, Noda Y, Miyazaki M, Mamiya T, Nozaki A, Nitta A, Sayed M, Assi AA, Gomaa A, Nabeshima T (2004) Molecular mechanisms in dizocilpine-induced attenuation of development of morphine dependence: an association with cortical Ca2+/calmodulin-dependent signal cascade. Behav Brain Res 152:263-270
14. Jhamandas KH, Marsala M, Ibuki T, Yaksh TL (1996) Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine. J Neurosci 16:2758-2766
15. Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A (2005) Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci Lett 378:131-134
16. Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD (1998) LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37:1-12
17. Klodzinska A, Chojnacka Wojcik E, Palucha A, Branski P, Popik P, Pilc A (1999) Potential anti-anxiety and anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38:1831-1839
18. Koyuncuoglu H, Dizdar Y, Ariciogly F, Sayin U (1992) Effects of MK-801 on morphine physical dependence: attenuation and intensification. Pharmacol Biochem Behav 43:487-490
19. Kozela E, Pilc A, Popik P (2003) Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology 165:245-251
20. Kupfenberg H (1964) A sensitive fluorometric assay for morphine in plasma and brain. J Pharmacol Exp Ther 145:247-251
21. Majer P, Jackson PF, Delahanty G, Grella BS, Ko YS, Li W, Liu Q, Maclin KM, Polakova J, Shaffer KA, Stoermer D, Vitharana D, Wang EY, Zakrzewski A, Rojas C, Slusher BS, Wozniak KM, Burak E, Limsakun T, Tsukamoto T (2003) Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 46:1989-1996
22. Maldonado R, Stinus L, Gold LH, Koob GF (1992) Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261:669-677
23. Mclemore GL, Kest B, Inturrisi CE (1997) The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence. Brain Res 778:120-126
24. Neale JH, Bzdega T, Wroblewska B (2000) N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 75:443-452
25. Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, Wroblewska B, Bzdega T, Vicini S, Barton FB, Neale JH (2004) NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 89:876-885
26. Palucha A, Branski P, Pilc A (2004) Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine withdrawal symptoms. Pol J Pharmacol 56:863-866
27. Popik P, Skolnick P (1996) The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol Biochem Behav 53:791-798
28. Popik P, Kozela E, Danysz W (2000a) Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Naunyn-Schmiedeberg's Arch Pharmacol 361:425-432
29. Popik P, Kozela E, Pilc A (2000b) Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. Br J Pharmacol 130:1425-1431
30. Popik P, Kozela E, Wrobel M, Wozniak KM, Slusher BS (2003) Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA. Neuropsychopharmacology 28:457-467
31. Rasmussen K, Aghajanian GK (1989) Withdrawal induced activation of locus coeruleus neurons in opiate dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain Res 505:346-350
32. Rasmussen K, Fuller RW, Stockton ME, Perry KW, Swinford RM, Ornstein PL (1991) NMDA receptor antagonists supress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur J Pharmacol 197:9-16
33. Rasmussen K, Hsu MA, Vandergriff J (2004) The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons. Neuropharmacology 46:620-628
34. Robinson MB, Blakely RD, Couto R, Coyle JT (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 262:14498-14506
35. Rojas C, Thomas AG, Majer P, Tsukamoto T, Lu XM, Vornov JJ, Wozniak KM, Slusher BS (2003) Glutamate carboxypeptidase II inhibition as a novel therapeutic target. Adv Exp Med Biol 524:205-213
36. Sanabria ER, Wozniak KM, Slusher BS, Keller A (2004) GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J Neurophysiol 91:182-193
37. Slusher BS, Vornov JJ, Thomas AG, Hum PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XC, Tortella FC, Wozniak KM, Yudkoff M, Potter BM, Jackson PF (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 5:1396-1402
38. Stinus L, Le Moal M, Koob GF (1990) Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 37:767-773
39. Tamaru Y, Nomura S, Mizuno N, Shigemoto R (2001) Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 106:481-503
40. Trujillo KA, Akil H (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85-87
41. Westbrook GL, Mayer ML, Namboodiri MA, Neale JH (1986) High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. J Neurosci 6:3385-3392
42. Wroblewska B, Wroblewski JT, Pshenichkin S, Surin A, Sullivan SE, Neale JH (1997) N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 69:174-181
43. Yamamoto T, Hirasawa S, Wroblewska B, Grajkowska E, Zhou J, Kozikowski A, Wroblewski J, Neale JH (2004) Antinociceptive effects of N- acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci 20:483-494
44. Zarrindast MR, Mousa-Ahmadi E (1999) Effects of GABAergic system on naloxone-induced jumping in morphine-dependent mice. Eur J Pharmacol 381:129-133
45. Zhao J, Ramadan E, Cappiello M, Wroblewska B, Bzdega T, Neale JH (2001) NAAG inhibits KCl-induced [(3)H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance. Eur J Neurosci 13:340-346